Latency Associated Peptide Has In Vitro and In Vivo Immune Effects Independent of TGF-β1
Open Access
- 2 April 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (4) , e1914
- https://doi.org/10.1371/journal.pone.0001914
Abstract
Latency Associated Peptide (LAP) binds TGF-β1, forming a latent complex. Currently, LAP is presumed to function only as a sequestering agent for active TGF-β1. Previous work shows that LAP can induce epithelial cell migration, but effects on leukocytes have not been reported. Because of the multiplicity of immunologic processes in which TGF-β1 plays a role, we hypothesized that LAP could function independently to modulate immune responses. In separate experiments we found that LAP promoted chemotaxis of human monocytes and blocked inflammation in vivo in a murine model of the delayed-type hypersensitivity response (DTHR). These effects did not involve TGF-β1 activity. Further studies revealed that disruption of specific LAP-thrombospondin-1 (TSP-1) interactions prevented LAP-induced responses. The effect of LAP on DTH inhibition depended on IL-10. These data support a novel role for LAP in regulating monocyte trafficking and immune modulation.Keywords
This publication has 39 references indexed in Scilit:
- Treatment with anti-TGF-β antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-β signalingKidney International, 2004
- Latency-Associated Peptide Prevents Skin Fibrosis in Murine Sclerodermatous Graft-Versus-Host Disease, a Model for Human SclerodermaJournal of Investigative Dermatology, 2003
- Transforming Growth Factor-β1 Mutations in Camurati-Engelmann Disease Lead to Increased Signaling by Altering either Activation or Secretion of the Mutant ProteinJournal of Biological Chemistry, 2003
- Allograft Acceptance Despite Differential Strain-Specific Induction of TGF-Ƴ/IL-10-MediatedImmunoregulationAmerican Journal of Transplantation, 2002
- CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolismJournal of Clinical Investigation, 2001
- Role of Transforming Growth Factor β in Human DiseaseNew England Journal of Medicine, 2000
- TRANSFORMING GROWTH FACTOR-?? AND INTERLEUKIN-10 SUBVERT ALLOREACTIVE DELAYED TYPE HYPERSENSITIVITY IN CARDIAC ALLOGRAFT ACCEPTOR MICE1Transplantation, 2000
- ALLOREACTIVE DELAYED-TYPE HYPERSENSITIVITY IN GRAFT RECIPIENTSTransplantation, 1997
- Identification of a chemotactic epitope in human transforming growth factor‐β1 spanning amino acid residues 368–374Journal of Cellular Physiology, 1995
- Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory diseaseNature, 1992